Silence Therapeutics plc (LON:SLN – Get Free Report) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 535 ($6.79) and traded as low as GBX 512 ($6.49). Silence Therapeutics shares last traded at GBX 535 ($6.79), with a volume of 913,528 shares trading hands.
Silence Therapeutics Stock Performance
The stock has a market capitalization of £480.35 million and a price-to-earnings ratio of -11.01. The stock’s 50 day moving average is GBX 535 and its 200 day moving average is GBX 535. The company has a current ratio of 4.52, a quick ratio of 4.36 and a debt-to-equity ratio of 0.80.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Recommended Stories
- Five stocks we like better than Silence Therapeutics
- How Technical Indicators Can Help You Find Oversold Stocks
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- What is a Dividend King?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
